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USE OF TORASEMIDE IN CATS FOR CONGESTIVE
HEART FAILURE. R. Mcdonald. University of Glasgow, Glas-
gow, UK
Torasemide is a loop diuretic which is more potent and of greater
persistency than furosemide. Torasemide is a potentially useful
treatment for dogs and cats in congestive heart failure (CHF) but is
only licensed for use in dogs in the UK. The aim of this study was to
describe the use of oral torasemide in cats with naturally occurring
CHF and to report tolerability and adverse eﬀects.
Two hospital databases were searched for cats with cardiac dis-
ease receiving torasemide from March 2014-March 2016; 11 client-
owned cats with suitable records were subsequently retrospectively
evaluated.
Collected data included signalment, presenting signs, diagnosis,
concurrent medications, maximum dose of furosemide before tran-
sition to torasemide, starting torasemide dose, maximum torase-
mide dose reached during CHF therapy, survival time after
commencing torasemide and comparison of renal parameters and
electrolytes prior-to and after commencing torasemide. Adverse
reactions were recorded. A board-certiﬁed cardiologist retrospec-
tively reviewed the cases. All owners signed consent forms to per-
mit the use of oﬀ-licensed drugs.
Cats included all had CHF and had acquired cardiomyopathy
or congenital cardiac disease conﬁrmed on echocardiography. All
were initially treated with furosemide; 55% were on oral therapy,
45% on intravenous therapy.
Various concurrent therapies included ACE inhibitors, spirono-
lactone, antithrombotics, pimobendan, diltiazem, atenolol, car-
bimazole, famotidine, mirtazapine. At initiation of torasemide,
cats were either poorly responsive to oral furosemide (n = 9) or
management was deemed more appropriate with torasemide
(n = 2).
The median dose of furosemide was 6 mg/kg/24 hrs (range 1–
10 mg/kg/24 hrs) prior to commencing torasemide. The median
initial dose of torasemide was 0.5 mg/kg/24 hr (0.1–0.75 mg/kg/
24 hrs) administered once or divided into twice daily dosing.
At the ﬁrst recheck there was a trend towards an increase in crea-
tinine and urea and a decrease in potassium. Azotaemia was
observed to be more marked in patients receiving a higher dose of
torasemide. During chronic therapy, torasemide was reduced in 3
cats due to increasing azotaemia.
At the time of writing, 5 cats were still alive. Mortality was due
to euthanasia for refractory CHF (n = 4), progressive azotemia
after starting torasemide (n = 1) and 1 cat was lost to follow up.
Median survival time was 48 d (7–177 d) with a median ﬁnal tora-
semide dose of 0.36 mg/kg/24 hrs (0.21–0.75 mg/kg/24 hrs).
Oral torasemide was tolerated by this population of cats with
CHF. The main adverse clinical eﬀect was worsening azotaemia.
Prospective studies are needed to further evaluate the use of tora-
semide in cats.
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IRON STATUS IN DOGS WITH MITRAL VALVE DISEASE.
A. Savarese, M. Probo, C. Locatelli, G. Traini, P.G. Brambilla, S.
Paltrinieri. University of Milan, Milano, Italy
In people, anemia and serum iron (SI) deﬁciency (SID) are fre-
quent co-morbidities in chronic heart failure (CHF). Recent stud-
ies showed that SID alone reduces quality of life and survival.
Mitral valve disease (MVD) is the most common acquired heart
disease in dogs, which can lead to CHF.
To the best of our knowledge, no studies have examined iron
status in MVD dogs.
The aims were to determine prevalence and characteristics of
SID (SI < 90 μg/dL) in dogs with MVD, to analyze diﬀerences in
SI among ACVIM classes, symptomatic and asymptomatic
patients, and to study the association between SID and survival.
Fifty privately owned MVD dogs admitted to the Cardiology
Service of DIMEVET (January 2015–April 2016) with complete
physical evaluation, chest x-ray, echocardiographic examination
and serum biochemical panel were included. Patients with other
heart or systemic diseases were excluded.
Blood samples were collected during routine clinical evaluation;
complete CBC and routine biochemistry were performed using an
automated laser hematology analyzer and automated spectropho-
tometer, while excess serum was frozen until analysis. Iron status
was evaluated measuring SI and total iron-binding capacity
(TIBC); percentage transferrin saturation (% SAT) was calculated.
The median age of dogs was 11 years (IQR 10–14) and median
body weight 11 kg (IQR 6–22). Most were intact males (42%).
The most represented breed was mongrel (46%). Twenty dogs
were ACVIM class B1 (40%), 12 B2 (24%), 15 C (30%) and 3 D
(6%). Non-symptomatic and symptomatic dogs were respectively
64% (n = 32) and 36% (n = 18).
The prevalence of SID in MVD dogs was 16% (8/50: 6 symp-
tomatic and 2 non-symptomatic). Only 3 patients (6%) presented
anemia (Hct ≤ 37%). TIBC was within or above the reference
range (NV: 270–496 lg/dL) in all dogs with SID, except one (re-
duced TIBC), while % SAT was below the minimum level (NV:
>23%) in 5/8 dogs (62%).
No diﬀerences in SI were found between ACVIM classes and
symptomatic/non-symptomatic patients.
Log-rank analysis showed shorter survival in MVD dogs with SID
(P value: 0.020), nevertheless multivariate Cox analysis showed
that only symptoms presence aﬀect survival.
Our results show that SID, although does not appear to inﬂu-
ence survival, is more common in symptomatic dogs and can be
occasionally present without anemia in dogs with MVD; TIBC and
% SAT values suggest that SID is most frequently true (primary
SID) than functional (secondary to inﬂammatory conditions).
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RELATIONSHIP BETWEEN ONE-DIMENSIONAL LEFT
ATRIAL PHASIC FUNCTION AND POST-CAPILLARY PUL-
MONARY HYPERTENSION IN DOGS WITH DEGENERA-
TIVE MITRAL VALVE DISEASE. A.C. Merveille, E. Roels, A.
Gautier, C. Clercx, K. Mc Entee. Faculty of Veterinary Medicine,
University of Liege, Liege, Belgium
Post-capillary pulmonary hypertension is common in dogs with
degenerative mitral valve disease (DMVD). Its prevalence increases
with severity of DMVD and its presence is a predictor of worse
outcome. Left atrial (LA) function and size are prognostic indica-
tors in DMVD. In dogs, LA contractile function has been shown
to decrease with severity of DMVD. In human with chronic mitral
regurgitation, LA function is an important correlate of right ven-
tricular systolic pressure. The aim of this study was to assess if LA
dysfunction was associated with PH in dogs with DMVD. Dogs
with DMVD and a measurable tricuspid regurgitation (TR) were
retrospectively recruited. Maximal LA diameter, LA diameter at
the onset of the P wave and minimal LA diameter were measured
on anatomic M-mode from 2D cineloops on aortic short axis view.
Left atrial reservoir (LA expansion index; Total LA shortening
fraction), conduit (Passive LA shortening fraction) and contractile
function (Active LA shortening fraction) indices were derived from
above measures. Ninety three dogs including ACVIM stage B1
(22), B2 (28), C (39) and D (4), were included. Dogs were assigned
to pulmonary hypertensive group (PH) (TR pressure gradient
>40 mmHg) (n = 29, median: 51 mmHg; range: 40–114) or pul-
monary normotensive group (PN) (n = 64, 29 mmHg; 5–40). LA
reservoir and contractile function indices were reduced in ACVIM
stage C and D compared to asymptomatic stages (P < 0.001) and
TR pressure gradient was higher in symptomatic dogs (P < 0.05)
compared to asymptomatic dogs. TR gradient was positively cor-
related with LA size measured at diﬀerent time intervals
(P < 0.001) and negatively correlated with LA reservoir (P = 0.02)
and contractile (P = 0.009) variables LA reservoir variables
(P = 0.008), and active LA shortening fraction (P = 0.006) were
lower in PH group compared to PN ANCOVA was used to test
the categorical eﬀect of ACVIM stages along with the eﬀects of
LA function indices on TR pressure gradient. ACVIM stage had a
strong eﬀect on TR gradient (P < 0.001) but LA function parame-
ters did not persist after correction for ACVIM stages. This study
conﬁrmed that, in dogs with DMVD, PH is strongly associated
with the stage of heart failure but failed to show an independent
relationship between LA dysfunction and development of PH. The
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